212 related articles for article (PubMed ID: 28387539)
1. Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy.
Ercolani C; Di Benedetto A; Terrenato I; Pizzuti L; Di Lauro L; Sergi D; Sperati F; Buglioni S; Ramieri MT; Mentuccia L; Gamucci T; Perracchio L; Pescarmona E; Mottolese M; Barba M; Vici P; De Maria R; Maugeri-Saccà M
Cancer Biol Ther; 2017 May; 18(5):339-346. PubMed ID: 28387539
[TBL] [Abstract][Full Text] [Related]
2. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
4. Effects of the hippo signaling pathway in human gastric cancer.
Zhou GX; Li XY; Zhang Q; Zhao K; Zhang CP; Xue CH; Yang K; Tian ZB
Asian Pac J Cancer Prev; 2013; 14(9):5199-205. PubMed ID: 24175801
[TBL] [Abstract][Full Text] [Related]
5. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Vici P; Ercolani C; Di Benedetto A; Pizzuti L; Di Lauro L; Sperati F; Terrenato I; Gamucci T; Natoli C; Di Filippo F; Botti C; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
J Exp Clin Cancer Res; 2016 Apr; 35():62. PubMed ID: 27039292
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.
He Z; Zhao TT; Jin F; Li JG; Xu YY; Dong HT; Liu Q; Xing P; Zhu GL; Xu H; Miao ZF
Biochem Biophys Res Commun; 2018 Sep; 503(4):2340-2347. PubMed ID: 29964010
[TBL] [Abstract][Full Text] [Related]
7. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
[TBL] [Abstract][Full Text] [Related]
9. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
[No Abstract] [Full Text] [Related]
10. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.
Vici P; Di Benedetto A; Ercolani C; Pizzuti L; Di Lauro L; Sergi D; Sperati F; Terrenato I; Dattilo R; Botti C; Fabi A; Ramieri MT; Mentuccia L; Marinelli C; Iezzi L; Gamucci T; Natoli C; Vitale I; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
Oncotarget; 2015 Dec; 6(40):42773-80. PubMed ID: 26544894
[TBL] [Abstract][Full Text] [Related]
11. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Yki/Yap subcellular localization and Hpo signaling by a nuclear kinase PRP4K.
Cho YS; Zhu J; Li S; Wang B; Han Y; Jiang J
Nat Commun; 2018 Apr; 9(1):1657. PubMed ID: 29695716
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
[TBL] [Abstract][Full Text] [Related]
14. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
16. Non-canonical Hippo signaling regulates immune responses.
Chen L
Adv Immunol; 2019; 144():87-119. PubMed ID: 31699221
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through phosphorylation of threonine 120.
Yuan Z; Kim D; Shu S; Wu J; Guo J; Xiao L; Kaneko S; Coppola D; Cheng JQ
J Biol Chem; 2010 Feb; 285(6):3815-3824. PubMed ID: 19940129
[TBL] [Abstract][Full Text] [Related]
18. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
[TBL] [Abstract][Full Text] [Related]
19. MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells.
Heidary Arash E; Shiban A; Song S; Attisano L
EMBO Rep; 2017 Mar; 18(3):420-436. PubMed ID: 28183853
[TBL] [Abstract][Full Text] [Related]
20. Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration.
Mi W; Lin Q; Childress C; Sudol M; Robishaw J; Berlot CH; Shabahang M; Yang W
Oncogene; 2015 Jun; 34(24):3095-106. PubMed ID: 25109332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
